Edition:
India

Profile: Auris Medical Holding Ltd (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

2.67USD
8:04pm IST
Change (% chg)

$-0.03 (-1.11%)
Prev Close
$2.70
Open
$2.73
Day's High
$2.82
Day's Low
$2.65
Volume
9,410
Avg. Vol
39,127
52-wk High
$39.20
52-wk Low
$2.42

Auris Medical Holding Ltd. is a clinical stage biopharmaceutical company. The Company is engaged in developing therapeutics for the neurotology and mental health supportive care.

The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). In addition the Company has two Phase 3 programs under development: Sonsuvi (AM-111) for acute inner ear hearing loss and Keyzilen (AM-101) for acute inner ear tinnitus.

Company Address

Auris Medical Holding Ltd

Bahnhofstrasse 21
ZUG   ZUG   6300
P: +4161.2011350

Company Web Links